Table 1. Clinical characteristic of the overall population and according to age.
| Variable | All cases | Group 1 (age <65 yr) | Group 2 (age ≥65 yr) | p-value | |
|---|---|---|---|---|---|
| Patients | 283 | 211 (74.6) | 72 (25.4) | - | |
| Mean age (yr) | 55.6±11.1 | 51±8.6 | 70±3.0 | 0.001 | |
| ECOG PS | 0.001 | ||||
| 0 | 259 (91.5) | 203 (96.2) | 56 (77.8) | ||
| 1 | 24 (8.5) | 8 (3.8) | 16 (22.2) | ||
| Comorbidities* | 0.001 | ||||
| 0 | 122 (43.1) | 111 (52.6) | 11 (15.3) | ||
| 1 | 88 (31.1) | 69 (32.7) | 19 (26.4) | ||
| 2 | 45 (15.9) | 21 (10.0) | 24 (33.3) | ||
| 3+ | 28 (9.9) | 10 (4.7) | 18 (25.0) | ||
| Comorbidities type | |||||
| Hypertension | 83 (29.3) | 44 (20.9) | 39 (54.2) | 0.001 | |
| Diabetes | 10 (3.5) | 4 (1.9) | 6 (8.3) | 0.020 | |
| Obesity | 5 (1.8) | 4 (1.9) | 1 (1.4) | 0.623 | |
| CV disease | 38 (13.4) | 20 (9.5) | 18 (25.0) | 0.001 | |
| GI disease | 18 (6.4) | 10 (4.7) | 8 (11.1) | 0.056 | |
| Pulmonary | 9 (3.2) | 2 (0.9) | 7 (9.7) | 0.001 | |
| Neurological | 25 (8.8) | 12 (5.7) | 13 (18.1) | 0.001 | |
| Other cancer | 0 | 0 | 0 | - | |
| Mean CR serum levels | 0.75±0.16 | 0.73±0.15 | 0.82±0.18 | 0.010 | |
| Mean eGFR CDK-EPI | 88.68±18.01 | 93.15±16.83 | 75.58±14.70 | 0.001 | |
| Mean of assumed drugs | 1.10±1.65 | 0.70±1.18 | 2.28±2.18 | 0.001 | |
| Histotype† | 0.591 | ||||
| HGS | 248 (92.5) | 186 (91.6) | 62 (95.4) | ||
| Endometrioid | 12 (4.5) | 10 (4.9) | 2 (3.1) | ||
| Other | 8 (3.0) | 7 (3.5) | 1 (1.5) | ||
| Tumor grade | 0.243 | ||||
| G1 | 7 (2.6) | 7 (3.4) | 0 | ||
| G2 | 7 (2.6) | 6 (3) | 1 (1.5) | ||
| G3 | 254 (94.8) | 190 (93.6) | 64 (98.5) | ||
| FIGO stage‡ | 0.267 | ||||
| I–II | 11 (3) | 9 (4.4) | 2 (3) | ||
| III–IV | 264 (93) | 198 (95.6) | 66 (97) | ||
| Surgical approach at primary surgery | 0.001 | ||||
| PDS | 191 (68) | 156 (74) | 35 (51) | ||
| NACT+IDS | 92 (32) | 55 (26) | 37 (49) | ||
| Perioperative complications§ | |||||
| Abscess | 1 (0.3) | 0 | 1 (1.5) | 0.082 | |
| Dehiscence | 2 (0.7) | 1 (0.4) | 1 (1.5) | 0.426 | |
| Sub-occlusion | 3 (1) | 3 (1.4) | 0 | 0.305 | |
| Sepsis | 2 (0.7) | 1 (0.4) | 1 (1.5) | 0.426 | |
| Bleeding | 1 (0.3) | 0 | 1 (1.5) | 0.082 | |
| Temporary/permanent stoma | 0.067 | ||||
| No | 242 (85) | 185 (88) | 57 (79) | ||
| Yes | 41 (15) | 26 (12) | 15 (21) | ||
| Chemotherapy regimen | 0.035 | ||||
| CBDCA-PTX-BEV (1st line) | 234 (82.7) | 168 (79.6) | 66 (91.7) | ||
| CBDCA-PTX-BEV (2nd line) | 12 (4.2) | 12 (5.7) | 0 (0.0) | ||
| CBDCA-GEM-BEV (2nd line) | 37 (13.1) | 31 (14.7) | 6 (8.3) | ||
Values are presented as number (%) or mean±standard deviation.
BEV, bevacizumab; CBDCA, carboplatin; CR, caloric restriction; CV, cardiovascular; ECOG PS, Eastern Cooperative Oncology Group performance status; eGFR CDK-EPI, estimated glomerular filtration rate according to Chronic Kidney Disease Epidemiology Collaboration equation [13]; FIGO, International Federation of Gynecology and Obstetrics; GEM, gemcitabine; GI, gastrointestinal; HGS, high-grade serous; NACT+IDS, neoadjuvant chemotherapy followed by interval debulking surgery; PDS, primary debulking surgery; PTX, paclitaxel.
*Patients might have experiences more than 1 comorbidity; †Data of 15 patients were missing; ‡Data of 8 patients were missing; §Within 30 days after surgery.